Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
J Cancer Res Ther ; 2005 Jul-Sep; 1(3): 129-31
Article in English | IMSEAR | ID: sea-111438

ABSTRACT

Potential of herbs and other plant-based formulations have been increasingly recognized in prevention and treatment of human diseases including cancer. There exist enormous prospect for screening and evaluation of herbal/plant products for developing effective radiosensitization and radioprotection relevant to nuclear research program. Investigations in our laboratory have focused on the mechanism of activity of variety of anticancer and antioxidant agents, namely, Eugenol, (EU), Ellagic acid (EA), Triphala (TPL), Tocopherol Succinate (TOS) and Arachidonic acid on normal and cancer cells with view to design effective protocols in practical radioprotection and cancer radiotherapy. This paper is mainly focused on studies on cytotoxic effects on cancer cell lines. Results have shown that these agents produced radiosensitizing action involving oxidative damage, membrane alteration and damage to nucleic acid in various human cell lines. Studies were performed employing fluorescence probes and electron spin resonance methods and gel electrophoresis protocols. It has been found that cytotoxic effect was induced by initiating membrane oxidative damage and by triggering intracellular generation of reactive oxygen species (ROS) by gamma radiation in combination with phytochemicals like TPL, EA and TOS in tumor cell line Ehrlich Ascites (EAC), Human cervical (HeLa) and breast (MCF-7) cells. Membrane damage and ROS generation was measured by DPH and DCF-FDA fluorescent probes respectively after exposure to low to moderate doses of gamma radiation. This talk will present the cytotoxic effects of phytochemicals in combination with ionizing radiation. It is emphasized that modulation of membrane peroxidative damage and intra cellular ROS may help achieve efficient killing of cancer cells which may provide a new approach to developing effective treatment of cancer.


Subject(s)
Apoptosis , Arachidonic Acid/therapeutic use , Combined Modality Therapy , Ellagic Acid/therapeutic use , Eugenol/therapeutic use , Humans , Lipid Peroxidation , Neoplasms/metabolism , Plant Extracts/therapeutic use , Radiation-Sensitizing Agents/therapeutic use , Reactive Oxygen Species/metabolism , Tocopherols , Vitamin E/analogs & derivatives
2.
Rev. Soc. Argent. Nutr ; 9(3): 49-54, 1998. ilus, tab
Article in Spanish | LILACS | ID: lil-226683

ABSTRACT

Introducción y objetivos: La ingestión de grasas durante el primer año de vida es fundamental no sólo para cubrir las necesidades energéticas sino también como fuente de nutrientes esenciales. Los objetivos del presente trabajo son los de evaluar el aporte de calorías grasas, ácido linoleico, relación ácido linoleico/ácido a-linolénico y agregado de ácidos grasos poliinsaturados de cadena larga en fórmulas infantiles. Material y Métodos: Se realizó un relevamiento de las fórmulas infantiles existentes en el mercado y se trabajó con información provista por los fabricantes. De las 34 fórmulas del mercado se seleccionaron 21 en base a leche de vaca y 4 a base de soja. Resultados: En todas las fórmulas el aporte de grasas se encontraba dentro de las cifras recomendadas. La mayoría tenía una relación ácido linoleico/ácido a-linolénico entre 5 y 15, de acuerdo a las recomendaciones, mientras que 5 de ellas la superaban. Ocho fórmulas presentaban un contenido de ácido linoleico fuera del rango recomendado. Sólo tres tenían ácido grasos poliinsaturados de cadena larga adicionados. Conclusiones: Los altos niveles de ácido linoleico y de la relación ácido linoleico/ácido a-linolénico en algunas fórmulas así como la falta de ácidos grasos poliinsaturados de cadena larga en la mayoría, podrían influir sobre el metabolismo lipídico y las funciones del sistema nervioso. Sin embargo, antes de proponer su adición en forma generalizada, sería importante realizar estudios sobre la forma más adecuada de hacerlo, teniendo en cuenta su biodisponibilidad y eventuales efectos adversos


Subject(s)
Humans , Infant, Newborn , Infant , Linoleic Acid/therapeutic use , /therapeutic use , Fatty Acids, Unsaturated/therapeutic use , Fatty Acids/therapeutic use , Breast-Milk Substitutes/analysis , Food, Formulated/analysis , Infant Food/analysis , Energy Intake/physiology , Lipids/analysis , Energy Requirement/physiology , Arachidonic Acid/analysis , Arachidonic Acid/therapeutic use , Fatty Acids, Essential/administration & dosage , Fatty Acids, Essential/chemistry , Amino Acids, Essential/administration & dosage , Child Development , Dietary Fats/pharmacokinetics , Docosahexaenoic Acids/analysis , Docosahexaenoic Acids/therapeutic use , Food, Formulated/classification
3.
Acta ortop. bras ; 5(3): 123-36, jul.-set. 1997. ilus, tab
Article in Portuguese | LILACS | ID: lil-212488

ABSTRACT

O imenso déficit neurológico decorrente da lesao da medula espinhal advém do somatório de dois eventos distintos: a lesao mecânica inicial e a lesao endógena secundária conseqüente à primeira. A lesao secundária da medula espinhal envolve complexas mudanças bioquímicas, que podem ser minimizadas pela introduçao de agentes farmacológicos recentes. Para limitar o dano tecidual e promover o reparo funcional, essas alteraçoes teciduais patológicas devem ser interrompidas. Avanços clínicos e científicos indicam que as lesoes agudas na medula espinhal podem ser manipuladas por terapêuticas farmacológicas utilizadas em curto espaço de tempo. A metilprednisolona administrada dentro das primeiras oito horas pós-trauma é o primeiro agente farmacológico a demonstrar melhora significativa na recuperaçao do trauma raquimedular em seres humanos. Outras drogas, como tilirazade e o GM-1, ainda sob investigaçao clínica, apresentam excelentes resultados preliminares. Esses avanços podem representar grande melhora na qualidade de vida de pacientes com lesao da medula espinhal, desde que sejam adotados pela prática clínica.


Subject(s)
Humans , Anti-Inflammatory Agents/therapeutic use , Methylprednisolone/therapeutic use , Spinal Cord Injuries/drug therapy , Arachidonic Acid/therapeutic use , Narcotic Antagonists/therapeutic use , Lipid Peroxidation
SELECTION OF CITATIONS
SEARCH DETAIL